{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:24Z","timestamp":1786979964579,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s00296-021-04904-5","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T04:03:28Z","timestamp":1622779408000},"page":"1265-1269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9200-5022","authenticated-orcid":false,"given":"Carolina","family":"Mazeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-1129","authenticated-orcid":false,"given":"Rita","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-8597","authenticated-orcid":false,"given":"Pedro Gon\u00e7alo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-8964","authenticated-orcid":false,"given":"Anabela","family":"Barcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1374-2738","authenticated-orcid":false,"given":"Renata","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"4904_CR1","doi-asserted-by":"publisher","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","volume":"3","author":"M Bottai","year":"2017","unstructured":"Bottai M et al (2017) International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 3:e000507. https:\/\/doi.org\/10.1136\/rmdopen-2017-000507 (PMID: 29177080; PMCID: PMC5687535)","journal-title":"RMD Open"},{"key":"4904_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/WCO.0000000000000855","volume":"33","author":"J Tanboon","year":"2020","unstructured":"Tanboon J et al (2020) Where are we moving in the classification of idiopathic inflammatory myopathies? Curr Opin Neurol 33:590\u2013603. https:\/\/doi.org\/10.1097\/WCO.0000000000000855 (PMID: 32852298)","journal-title":"Curr Opin Neurol"},{"key":"4904_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/CND.0000000000000065","volume":"16","author":"C Quinn","year":"2015","unstructured":"Quinn C et al (2015) Necrotizing myopathies: an update. J Clin Neuromuscul Dis 16:131\u2013140. https:\/\/doi.org\/10.1097\/CND.0000000000000065 (PMID: 25695918)","journal-title":"J Clin Neuromuscul Dis"},{"key":"4904_CR4","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.semarthrit.2019.04.002","volume":"49","author":"JA Day","year":"2019","unstructured":"Day JA et al (2019) Immune-mediated necrotising myopathy: a critical review of current concepts. Semin Arthritis Rheum 49:420\u2013429. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.04.002 (Epub 2019 Apr 25 PMID: 31109639)","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"4904_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","volume":"20","author":"I Pinal-Fernandez","year":"2018","unstructured":"Pinal-Fernandez I et al (2018) Immune-mediated necrotizing myopathy. Curr Rheumatol Rep 20(4):21. https:\/\/doi.org\/10.1007\/s11926-018-0732-6 (PMID: 29582188; PMCID: PMC6019613)","journal-title":"Curr Rheumatol Rep"},{"key":"4904_CR6","unstructured":"Allenbach Y et al (2017) Immune-Mediated Necrotizing Myopathies Working Group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscular Disorders"},{"key":"4904_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","volume":"18","author":"C Anquetil","year":"2019","unstructured":"Anquetil C et al (2019) Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmun Rev 18:223\u2013230. https:\/\/doi.org\/10.1016\/j.autrev.2018.09.008 (Epub 2019 Jan 11. PMID: 30639649)","journal-title":"Autoimmun Rev"},{"issue":"12","key":"4904_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y et al (2020) Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol 16(12):689\u2013701. https:\/\/doi.org\/10.1038\/s41584-020-00515-9 (Epub 2020 Oct 22 PMID: 33093664)","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"4904_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"13","author":"S Suzuki","year":"2015","unstructured":"Suzuki S et al (2015) Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 13(10):61. https:\/\/doi.org\/10.1186\/s13023-015-0277-y (PMID: 25963141; PMCID: PMC4440264)","journal-title":"Orphanet J Rare Dis"},{"key":"4904_CR10","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","volume":"15","author":"ER McGrath","year":"2018","unstructured":"McGrath ER et al (2018) Autoimmune myopathies: updates on evaluation and treatment. Neurotherapeutics 15:976\u2013994. https:\/\/doi.org\/10.1007\/s13311-018-00676-2 (PMID: 30341597; PMCID: PMC6277300)","journal-title":"Neurotherapeutics"},{"key":"4904_CR11","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","volume":"16","author":"JB Arlet","year":"2006","unstructured":"Arlet JB et al (2006) Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 16:334\u2013336. https:\/\/doi.org\/10.1016\/j.nmd.2006.03.002 (Epub 2006 Apr 17 PMID: 16616848)","journal-title":"Neuromuscul Disord"},{"key":"4904_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/rheumatology\/kep027","volume":"48","author":"BR Whelan","year":"2009","unstructured":"Whelan BR et al (2009) Poor response of anti-SRP-positive idiopathic imune myositis to B-cell depletion. Rheumatology (Oxford) 48:594\u2013595. https:\/\/doi.org\/10.1093\/rheumatology\/kep027 (Epub 2009 Mar 1 PMID: 19254917)","journal-title":"Rheumatology (Oxford)"},{"key":"4904_CR13","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R et al (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 62:1328\u20131334. https:\/\/doi.org\/10.1002\/acr.20219 (PMID: 20506493; PMCID: PMC3107255)","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4904_CR14","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/rheumatology\/ker305","volume":"50","author":"M Couderc","year":"2011","unstructured":"Couderc M et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50:2283\u20132289. https:\/\/doi.org\/10.1093\/rheumatology\/ker305 (Epub 2011 Oct 22. PMID: 22019807)","journal-title":"Rheumatology (Oxford)"},{"key":"4904_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I et al (2017) Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken) 69:263\u2013270. https:\/\/doi.org\/10.1002\/acr.22920 (Epub 2016 Dec 31. PMID: 27111848; PMCID: PMC5079847)","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"4904_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/practneurol-2018-002168","volume":"19","author":"P Mehta","year":"2019","unstructured":"Mehta P et al (2019) Difficult case: rituximab in anti-SRP antibody myositis in pregnancy. Pract Neurol 19:444\u2013446. https:\/\/doi.org\/10.1136\/practneurol-2018-002168 (Epub 2019 Apr 12 PMID: 30979789)","journal-title":"Pract Neurol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04904-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T05:08:06Z","timestamp":1655356086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04904-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["4904"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04904-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carolina Mazeda and Rita Cunha declare that they have no conflict of interest. Renata Aguiar has received honoraria for speaking from UCB and Bial. Pedro Gon\u00e7alo Ferreira has received honoraria for speaking from Boehringer-Ingelheim, Roche, Medinfar, Glaxo, Novartis, Menarini and Mundipharma. Pedro Gon\u00e7alo Ferreira has received honoraria for consultancy from Boehringer-Ingelheim and Roche. Anabela Barcelos has received honoraria for speaking at symposia\/position on advisory board: MSD, Novartis, Lilly, Pfizer. Carolina Mazeda is the corresponding author. She takes responsibility for the integrity of the data and data analysis accuracy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient in our case report has signed a written consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}